We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Advanced Prostate Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Gregory Lewis
Mar 19, 2021
4 - pembrolizumab
In prostate cancer, CDK12 mutations occur in 5%−7% of patients with mCRPC, and most are biallelic inactivations.
CDK12-altered/mutated prostate cancer is an aggressive subtype with poor responses and outcomes to hormonal, taxane, and PARP inhibitor therapies. A proportion of these patients may respond favorably to PD-1 inhibitors, which implicates CDK12 deficiency in immunotherapy sensitivity.
Juan Artigas
Mar 19, 2021
He should be treated with cabazitaxel and pembrolizumab. CDK12 does not respond to PARP inhibitors.
Bahram Mofid
Mar 23, 2021
He should be treared with pembrolizumab
Charles Maack
May 07, 2021
pembrolizumab as explained by Gregory Lewis
Noureddine Benjaafar
Jun 12, 2021
Pembroluzumab or cabazitaxel
silvia scalbi
May 18, 2022
cabazitaxel
Charles Maack
May 19, 2022
Will we ever be provided what subsequent protocol was followed or what the author was aware in advance when we participate in these questions for our opinion?
Apr 19, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Pedro
C.
Barata
MD
Gregory Lewis
Mar 19, 2021
Juan Artigas
Mar 19, 2021
Bahram Mofid
Mar 23, 2021
Charles Maack
May 07, 2021
Noureddine Benjaafar
Jun 12, 2021
silvia scalbi
May 18, 2022
Charles Maack
May 19, 2022
Apr 19, 2024
Pending Moderator approval.